The investigational regimen of Glecaprevir/Pibrentasvir (G/P), which is now under accelerated assessment by EMA, is used as treatment for patients affected with genotypes 1-6 of the hepatitis C
The trial, Maestro, had enrolled 226 patients, with 135 of them in Functional Class II and was randomized in a 1:1 ratio. While one patient group was subjected to
Financial terms of the exclusive sub-license agreement, which was signed with SATT Sud-Est, were not disclosed. Inserm, the National Center for Scientific Research, the University of Cote d'Azur,
Last month, the company had begun a phase 2 trial in the US for studying CTP-656 in patients with cystic fibrosis and having gating mutations. The phase 2 trial’s
As part of the settlement and license agreement, all claims in the relevant legal proceedings will be dismissed, and the companies have granted certain patent rights to each
Azaya is engaged in the development of more effective cancer treatments through its novel nanotechnology platform. The company’s patented Protein Stabilized Liposomes platform enables for high-dose delivery of
The Ireland based pharma maintained that it did not admit to any wrongdoing in the acquisition deal of synthetic ACTH product Synacthen Depot by Questcor Pharmaceuticals from Novartis
Under the terms of the deal, which is anticipated to close by the end of the first quarter of this year, Lilly will pay $46.50 a share for
The deal, which gives Biogen a license to Forward Pharma’s intellectual property, could help the US company extend the life of Tecfidera. Under several circumstances outlined in the deal, Biogen will
The trial’s original objective was the effect on progression-free survival (PFS) but the company has now added overall survival (OS), both for the combination and durvalumab monotherapy. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.